As the first half of 2025 concludes, MedRobot has compiled exclusive procurement data from China’s public hospitals regarding surgical robots. From January 1 to June 30, a total of 74 surgical robots were awarded in public tenders, with a combined contract value exceeding 700 million RMB (~96 million USD). The majority of these procurements came from laparoscopic, orthopedic, and neurosurgical categories.

Compared to previous years, the market continues to show steady growth, alongside two notable trends:

1. Accelerated expansion into Tier 2 cities

2. Wider breakthroughs from domestic brands

A detailed breakdown by surgical category is provided below.

Laparoscopic Surgical Robots

• Units Awarded: 25

• Total Value: ~430 million RMB (~59 million USD)

• Leading Brands:

  • Intuitive/da Vinci

  • Edge Medical

  • Medbot

  • Cornerstone Robotics

  • SHURUI

Orthopedic Surgical Robots

• Units Awarded: 26

• Total Value: ~250 million RMB (~34 million USD)

• Leading Brands:

  • TINAVI

  • Jianjia Medical

  • Tuodao Medical

  • Yuanhua Robotics

Neurosurgical Robots

• Units Awarded: 19

• Total Value: ~50 million RMB (~6.8 million USD)

• Leading Brands:

  • Baihui Weikang/Remebot

  • Sinovation

  • Medtronic

Other Categories

• Natural Orifice Robots: 2 units (Johnson & Johnson, LungHealth MedTech)

  

• Dental Robots: 1 unit (Yakebot)

  

• Puncture Robots: 1 unit (TrueHealth)

  

Outlook for the Second Half of 2025

The first half of 2025 confirms a stable yet expanding procurement landscape in China’s public hospitals. Laparoscopic systems remain the market backbone, orthopedic robotics are entering a high-growth phase, and neurosurgical solutions continue to gain ground. Meanwhile, niche categories such as dental and natural orifice robots have started to appear in small numbers.

International brands still dominate the laparoscopic segment, driven by mature surgical workflows and robust service networks. However, domestic players are advancing rapidly, particularly in orthopedics, thanks to their competitive pricing, faster local support, and improved procedural adaptability.

Looking ahead, a procurement surge is expected in the second half, spurred by equipment renewal cycles and the rollout of local funding programs. For Chinese manufacturers, sustained success will hinge on strengthening delivery reliability, clinical usability, and after-sales coverage.

We welcome additional insights and data from industry professionals to help us keep this report comprehensive and current.

By MedChina/MedRobot, July 23, 2025